Evidence map›Paper›PMID 35609324›Full record

ArticleBioengineered2022

Gastrodin protects retinal ganglion cells from ischemic injury by activating phosphatidylinositol 3-kinase/protein kinase B/nuclear factor erythroid 2-related factor 2 (PI3K/AKT/Nrf2) signaling pathway.

Sizhen Li, Qingsong Yang, Zixiu Zhou, Xiaodong Yang, Yating Liu, Kuanxiao Hao, Min Fu

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. [Geniposide inhibits retinal cell apoptosis induced by glaucoma through the Hspa1a pathway].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Gastrodin: a comprehensive pharmacological review.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review on pharmacological effects of gastrodin.Archives of pharmacal research · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sizhen LiNanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, P.R. China.
Qingsong YangNanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, P.R. China.
Zixiu ZhouNanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, P.R. China.
Xiaodong YangNanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, P.R. China.
Yating LiuNanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, P.R. China.
Kuanxiao HaoNanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, P.R. China.
Min FuNanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, P.R. China.
Southeast University · CNTongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is a progressive optic neuropathy and improper treatment may cause irreversible damage to visual function. Gastrodin is an effective active substance extracted from Gastrodia elata and possesses antioxidant as well as anti-inflammatory properties. However, the therapeutic potential of gastrodin for retinal ischemia/reperfusion (I/R) injury remains unclear. We adopted oxygen and glucose deprivation/reoxygenation (OGD/R) to induce R28 cells with the aim of simulating glaucomatous neurodegeneration. CCK-8 analysis and TUNEL were applied for examining cell proliferation and apoptosis . In addition, RT-qPCR and ELISA were performed to test the releases of inflammatory factors in cells . Related indicators of intracellular oxidative stress and ROS production were detected by corresponding kits. Moreover, western blot was applied to assay the expressions of PI3K/AKT/Nrf2 pathway-related proteins. OGD/R induction contributed to the decreased cell viability and reduced Bcl-2 protein expression, while the protein contents of Bax, Cyto-C, c-caspase 9 and c-PARP as well as ROS production were ascended. The co-treatment of hypoxia and gastrodin greatly improved R28 cell viability but effectively suppressed cell apoptosis, ROS level and the releases of OGD/R-induced inflammatory factors as well as oxidative stress. In addition, OGD/R stimulation reduced Nrf2, accompanied by a decrease in the phosphorylation levels of PI3K and AKT. Gastrodin significantly promoted the activation of PI3K/AKT/Nrf2 signaling pathway in R28 cells, which was then counteracted by PI3K/AKT inhibitors. In conclusion, the present study suggested that gastrodin has a protective effect on OGD/R-induced R28 cell injury, which is achieved through the activation of the PI3K/AKT/Nrf2 signaling pathway.

Indexed as

Proto-Oncogene Proteins c-aktReperfusion InjuryApoptosisBenzyl AlcoholsGlucoseGlucosidesHumansIschemiaNF-E2-Related Factor 2Oxidative StressOxygenPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesReactive Oxygen SpeciesRetinal Ganglion CellsSignal TransductionBenzyl AlcoholsgastrodinGlucoseGlucosidesNF-E2-Related Factor 2OxygenPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesapoptosisGastrodinischemic injuryoxidative stressPI3K/AKT/Nrf2 pathway

Identifiers

PMID35609324
PMCPMC9275977
OpenAlexW4282927613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.